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Abstract. The structural gene for yeast vacuolar car- 
boxypeptidase Y (PRC1) has been cloned by comple- 
mentation of the prcl-1 mutation. As much as an 
eighffold elevation in the level of carboxypeptidase Y 
(CPY) results when a multiple-copy plasmid contain- 
ing the PRC1 gene is introduced into yeast. Unlike 
the situation with a single copy of PRC1 in which 
newly synthesized CPY is efficiently localized to the 
vacuole, plasmid-directed overproduction results in 
secretion of >50% of the protein as the precursor 
form. Secretion is blocked in a mutant that is defec- 
tive at a late stage in the transport of periplasmic 
proteins. Unlike normal cell surface glycoproteins, se- 
creted CPY precursor acquires no additional oligosac- 
charide modifications beyond those that accompany 
normal transport to the vacuole. In the periplasm, the 
CPY precursor is proteolytically activated to an enzy- 
matically active form by an enzyme that is unrelated 
to the vacuolar processing enzyme. These findings 
suggest that proper sorting and transport of CPY is 
saturable. This may reflect limiting amounts of a 
CPY-sorting receptor, or of CPY-modifying machin- 
ery that is essential for recognition by such a receptor. 
T 
HE secretory pathway in yeast,  as in  more complex 
eukaryotic ceils, is required for the transport of hydro- 
lytic enzymes to the lysosome-like  vacuole (22, 23). 
For example, yeast sec mutants blocked in transport from the 
endoplasmic reticulum or from the Golgi body fail to trans- 
port carboxypeptidase Y (CPY) ~  to the vacuole (29). Precursor 
forms of this protein accumulate at a restrictive temperature 
in this class of sec mutant cells and transport is restored when 
cells are returned to a permissive temperature. CPY transport 
to the vacuole proceeds normally in sec mutant cells blocked 
after the Golgi body step. These findings indicate that sorting 
of vacuolar and secretory proteins occurs at or before the 
Golgi body. 
Unlike the targeting of lysosomal proteins in animal cells, 
transport of CPY to the vacuole in yeast does not require a 
carbohydrate determinant (26). In mammalian fibroblasts, a 
mannose-6-phosphate determinant directs transport of most 
lysosomal glycoproteins from the Golgi body to the lysosome 
(7, 10, 16). Nevertheless, protein structure must ultimately be 
responsible for targeting proteins to the lysosome. Lang et al. 
(18) have shown that lysosomal glycoproteins are much better 
substrates  for the transfer of the N-acetyl-glucosamine-phos- 
phate lysosomal targeting signal than similarly modified se- 
cretory glycoproteins.  In order to develop a genetic means of 
1. Abbreviations used in this paper." CEN, single-copy centromere-containing 
plasmid; CPY, carboxypeptidase Y; E fraction, extracellular fraction; endo F, 
endoglycosidase F; I fraction, intracellular fraction; M fraction, medium frac- 
tion; MV-pro, minimal medium with proline as the nitrogen source; P fraction, 
periplasmic fraction; proCPY, CPY precursor; 2~, multi-copy 2-micron plas- 
mid. 
identifying the signal(s) on CPY involved in transport of the 
polypeptide to the vacuole, we have cloned the CPY structural 
gene (PRC1). 
In this report we show that when the PRC1 gene is intro- 
duced into yeast on a multiple-copy 2-micron plasmid (2~), 
the resulting overproduction of CPY leads to secretion of a 
large fraction of the newly synthesized enzyme. These results 
suggest that CPY transport may be mediated by a saturable 
component. 
Materials and Methods 
Strains, Growth Conditions, and Materials 
A prcl-1 strain (34) was obtained from G. Fink (Whitehead Institute, Boston, 
MA),  and strain SEY5016a,  (secl-1,  leu2-3,  leu2-112,  ura3-52,  gal2)  was 
provided by S.  Emr (Caltech, Pasadena, CA). SF838-5Aa (leu2-3,  leu2-112, 
ura3-52, ade6), SF838-1Da (pep4-3, leu2-3,1eu2-112,  his4-519,  ura3-52, ade6), 
and  ISYI-7Ba (pho80,  leu2-3,  1eu2-112,  ura3-52,  his4,  suc2A9)  were  con- 
structed by standard genetic techniques. Bacterial  transformations were per- 
formed with Escherichia coli strain  MCI061  (F-hsdR-  hsdM  + araD139A 
(araABOIC-leu) 7679A(lac)X74 galU galK rpsL) obtained from S. Emr. 
Yeast extract-peptone dextrose medium contained 1% Bacto-Yeast Extract 
(Difco Laboratories, Inc., Detroit, MI), 2% Bacto-Peptone (Difeo Laboratories, 
Inc.), and 2% glucose. Wickerham's minimal medium (33) was used with the 
following  modifications: for sulfate-free  medium, chloride salts replaced all 
sulfate salts; for minimal medium with proline as the nitrogen source (MY- 
pro),  1% proline replaced  ammonium sulfate and Na2SO+ was added to  10 
mM (except in radiolabeling experiments). Supplements of leucine (30 #g/ml), 
uracil (20 t~g/ml), histidine (20/~g/ml), and adenine (3'0 jzg/ml) were added as 
needed. Unless otherwise indicated, the carbon source was 2% glucose and the 
yeast cultures were grown at 30"C with agitation. The absorbance of dilute cell 
suspensions  was measured in a l-cm cuvette at 600 nm in a spectrophotometer 
(model DU6; Beckman Instruments, Inc., Fullerton, CA); 10D6oo unit of cells 
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with exponentially growing cells at an ODro0 of 0.5-2. 
N-CBZ-L-Phenylalanyl-L-leucine, L-amino acid oxidase, horseradish perox- 
idase, and o-dianisidine were from Sigma Chemical Co. (St. Louis, MO); aSS- 
H2SO4 was from ICN K&K Laboratories Inc. (Plainview, NY); IgG Sorb was 
from the Enzyme Center (Boston, MA); restriction endonucleases, acetylated 
BSA and T4 DNA ligase were from Bethesda Research Laboratories, Gaithers- 
burg, MD; endoglycosidase F (endo F) was from Boehringer Mannheim Diag- 
nostics  Inc.  (Houston,  TX).  Fraction  II  Lyticase  was  used  in  spheroplast 
preparation (27). Affinity-purified CPY antibody was described previously (29). 
Plasmid Vectors and Recombinant DNA Methodology 
Restriction  endonuclease  digestions and ligations with T4  DNA ligase were 
carried out as recommended  by the suppliers. Plasmid purification, agarose gel 
electrophoresis,  and  DNA-mediated  transformations  of bacteria  were  per- 
formed by standard  methods (1, 19). A yeast genomic clone bank constructed 
in the LEU2 vector YEpl3 (21) was used to complement  the prcl-1 mutation 
in cloning PRC1. The YEpl3 plasmid containing the genomic PRC1 insert is 
pTSY1. Plasmid pTSY3 was constructed  by subcloning the 3.2-kb Pvu II-Sal I 
fragment from pTSY1 into the Pvu II and Sal I sites of the multiple-copy 2u 
circle plasmid YEp24 (2u-PRCI, 2) and pTSYI000 (single-copy centromere- 
containing  plasmid  (CEN)-PRCI)  was constructed  by  inserting  the  3.7-kb 
EcoRI-Sal I fragment into the EcoRI and Sal I sites in the single-copy plasmid 
YCp50  (17, 31)  which  contains  the  centromere  region  of chromosome 4 
(CEN4). Subcloned plasmids were introduced  into yeast cells by the lithium 
acetate transformation  method (13). 
A chromosomal PRC1 deletion  was constructed  by transplaeing  (25) the 
genomic copy with the cloned gene into which the LEU2 gene was inserted in 
place of a majority  of the PRCI coding region, pTSYI000 was treated  with 
BamH I followed by S 1 nuclease. A 2.2-kb Sal I-Xho I fragment containing the 
LEU2 gene on YEpl 3 was removed and treated with S 1 nuclease. The two cut 
plasmid  samples  were mixed  and treated  with  T4  DNA ligase. A  plasmid 
conferring Amp" Leu  ÷ Ura  + was selected in a suitably marked  E. coli strain; 
restriction analysis showed that the LEU2 fragment had been inserted in the 
PRCI gene in pTSY 1000. A Hindlll-Sal I fragment containing the LEU2 gene 
with PRC1 flanking sequences was cut from this plasmid and used to transform 
a PRC1 pep4-3 leu2-3  leu2.112 yeast strain.  Stable Leu  + transformants were 
purified  and screened  for immunoprecipitable  CPY.  One was selected that 
produced no detectable immunoreactive  CPY (Aprcl) and this strain was used 
to generate yeast crude extract lacking CPY. To prepare  a Aprcl cell extract 
Aprcl cells were centrifuged, resuspended to 10 ~° cells/ml in 25 mM potassium 
phosphate,  pH 7.5, 0.2 M NaCI, followed by cell breakage in a homogenizer 
(Manton-Gaulin,  Everett, MA). SDS was added to 1% final concentration,  the 
extract was heated  in a boiling water bath for 5 min, followed by a  15-min 
centrifugation in a microfuge to yield a supernatant that was used as a Aprcl 
crude extract. 
Enzyme Assay 
Periplasmic and total CPY enzyme activities were measured by a modification 
of the coupled peptidase assay (35). Cells were grown to mid-log phase (ODt0o 
of 1-2) in minimal medium and sedimented in a clinical centrifuge. For assay 
of periplasmic enzyme, cells were washed in 0.2 M potassium phosphate, pH 
7.0; for assay of total activity cells were washed in 0.2 M phosphate buffer plus 
1% Triton X-100. After resedimentation,  cells were resuspended in 0.2 ml of 5 
mM N-CBZ-L-phenylalanyl-L-leucine in 0.2 M potassium phosphate, pH 7.0, 
without (for periplasmic) or with (for total) 0.2% Triton X-100. Samples were 
incubated  at 37"C for 30 min with gentle agitation, then heated in a boiling 
water  bath  for 3  rain  to stop the  peptidase  reaction.  Released leucine  was 
measured by the addition of I ml of 0.2 M potassium phosphate containing  15 
~1 10 mg/ml L-amino acid oxidase, 10 ~1 1 mg/ml horseradish peroxidas¢, 30 
#l 10 mg/ml o-dianisidine, and 25 #l 20 mM N-ethyl-maleimide. After 30 min 
at 37"C, 1 ml of 6 N HCI was added and the sample was centrifuged for 2 min 
in a mierofuge (Fischer Scientific Co., Pittsburgh, PA). The A54o of the super- 
natant solution was recorded: one unit is 1 gmol L-leucine released per minute 
and specific activity is given in milliunits per microgram dry weight. 
A plate-staining procedure for CPY activity developed by E. Jones (14) was 
used to screen for PRCI transformants. 
RadiolabeHng, Endo F 
Treatment, and lmmunoprecipitation 
Yeast cells were grown in MV-pro medium containing  50 #M sulfate to mid- 
log  phase,  centrifuged,  washed  once  in  sulfate-free  MV-pro  medium  and 
suspended  in  fresh  MV-pro  medium  containing  0.5  mg/ml bovine  serum 
albumin (BSA), unless otherwise indicated,  and no added  sulfate. 3~S-H2SO4 
was added (100-1,000  #Ci) and cells were labeled for 15 min, at which time 
unlabeled Na2SO4 was added  to  10 mM final concentration.  A chase period 
followed for either 45 or 165 rain. Labeled cells were fractionated into secreted 
and internal fractions. 
For separation of secreted from internal fractions, cells labeled in 0.5 ml of 
medium were sedimented  in a mierofuge and the supernatant  medium (M) 
fraction was saved. The cell pellet was resuspended in 0.15 ml of 1.4 M sorbitol, 
50 mM Tris-HCl (pH 7.5), 20 mM 2-mercaptoethanol,  2 mM MgCI2, 20 mM 
NAN3, and  50  U  lyticase/OD~o  unit cells. Spheroplasts  formed  during  the 
subsequent 45-min incubation at 30°C were sedimented in a microfuge and the 
supernatant (P) and pellet  fractions  (intracellular,  I) were separated.  The P 
fraction was adjusted to >0.5% SDS by the addition of 10 #1 of 10% SDS plus 
30 #l Apr¢l cell extract, and the I fraction was resuspended in 0.1  ml of 1% 
SDS plus 30 zl Aprcl extract; both were heated in a boiling water bath for 3 
min. Fractions were diluted to 1 ml with 12 mM potassium phosphate, pH 7.5, 
0.2 M NaC1, 2% Triton X-100, followed by addition  of 0.1  ml ofIgG Sorb 
(prepared as suggested by the manufacturer).  The mixture was centrifuged in a 
mierofuge and the supernatant fraction  was treated  with  sufficient affinity- 
purified CPY antibody  to precipitate  all the CPY antigen in 90 min at 0°C. 
Another aliquot  of IgG Sorb was added and after 30 min at 0oc the immune 
complexes were sedimented and washed as before (29). Sample buffer (50 mM 
Tris-HCl,  pH  6.8, 10%  glycerol,  2%  SDS,  2%  2-mercaptoethanol,  0.01% 
bromphenol blue) was added and the samples were heated in boiling water for 
2 min and centrifuged.  Supernatant  solutions  were transferred  to new tubes 
and equal aliquots were taken for SDS-gel electrophoresis as before (29). After 
electrophoresis  gels were  fixed, permeated  with  sodium salicylate (15) for 
fluorography, dried, and exposed to Kodak XAR-5 film at -80"C. 
Endo F treatment (4) was carried out on immunoprecipitated  samples of 
CPY. The washed IgG Sorb-immune complexes were heated in sample buffer 
at  100*C for 2 min. After removal of the IgG Sorh by centrifugation for 3 min 
in a microfuge the protein was precipitated from the supematant by the addition 
of 4 vol of ice-cold acetone. After 30 min at -80"C the tubes were centrifuged 
in a  microfuge for  10  min, the pellets were dried  under vacuum,  and  then 
resuspended in  10 #1 of I% SDS. The tubes were heated at  100"C for 2 min 
and diluted to 100 ~1 in 50 mM potassium phosphate, pH 6.6, 50 mM EDTA, 
1% Triton X- 100, and 1% B-mercaptoethanol. Approximately 300 mU of  endo 
F (4) were added  and the solution  incubated  at 37*C for 48 h. Sample buffer 
was added, the tube heated in a boiling water bath for 2 min, and the samples 
electrophoresed as above. 
Quantitation  of CPY antigen was carried out by cutting out the appropriate 
CPY bands from the autoradiogram  and eluting silver grains with NaOH (32). 
This procedure allowed quantitation  of the relative levels of CPY synthesis in 
cells carrying  different  plasmids;  these  numbers were  normalized  for total 
protein synthesis (29). To determine  the extent of CPY secretion, the intensity 
of CPY bands in the secreted (P and M) fractions was summed and compared 
with the total CPY synthesized (I +  P +  M). The percentage of secretion of 
CPY is thus 100 (P + M)/(I + P + M). 
Results 
Cloning of PRC1 
Hemmings et al. (12) demonstrated that the gene identified 
by Wolf  and Fink (34) was the structural gene for CPY (PRC1) 
by isolating  strains bearing nonsense mutations at the PRC1 
locus,  at least  one of which produces a truncated immuno- 
reactive  fragment of the enzyme. In order to clone the PRC1 
gene, a prcl-1 leu2-3 leu-2-112 yeast strain was transformed 
with  a  YEpI3 (LEU2)  yeast genomic bank  (21)  and  Leu  + 
transformants were selected.  About 20,000  Leu  + transform- 
ants were tested  for CPY activity using the CPY plate stain 
(13);  16 positive colonies were detected.  Quantitative assays 
of extracts of these transformants showed only one that con- 
tained CPY activity.  Plasmid  DNA was isolated  from this 
transformant and introduced into E. coli.  One class ofplasmid 
was obtained (pTSY1),  and a restriction map of the genomic 
insert  in this plasmid is shown in Fig.  1. pTSYI propagated 
in E. coli restored the wild-type  Prc+ phenotype when intro- 
duced into the prcl yeast strain.  Enzyme activity measure- 
ments revealed  an approximately fourfold increase  in CPY 
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Figure 1. PRC1 insert cloned from the YEpI3 yeast library. The 2.6- 
kb Pvu II-Cla I fragment is the smallest subclone that complements 
the prcl-1 mutation. Abbreviations: A, Acc I; B, BamHI; C, Cla I; 
E, EcoRI; H, HindlII;  P, Pvu II; S, Sal I. The sequence encoding 
CPY is represented by the hatched box. 
activity in transformants relative to wild-type untransformed 
cells (not shown). 
The  smallest  subcloned  region  of the  PRCI  insert  that 
complemented the prcl-1 mutation was the 2.6-kb Pvu II-Cla 
I fragment. This DNA fragment actually includes the PRC1 
gene since  it  maps genetically to  the  PRC1  locus:  a  strain 
deleted for most of the putative PRC1  open reading frame 
and carrying the LEU2 marker (see Materials and Methods) 
was crossed to a prcl-1 strain, diploids were selected, sporu- 
lated, and asci dissected. In 20 asci the Prc phenotype segre- 
gated 0+:4  -, demonstrating that the integrated cloned gene is 
tightly linked to the PRC1  (CPY structural gene) locus.  In 
addition, the DNA sequence of the cloned PRC1 gene con- 
firms that it codes for the vacuolar protease CPY (Vails,  L. 
A., and T. H. Stevens, manuscript in preparation). 
Secretion of CPY is Dependent on PRC1 
Gene Copy Number 
To determine if any overproduced CPY escapes the normal 
sorting  reaction  in  the  Golgi body,  cells  transformed with 
pTSY3 or YEp24 were fractionated into I, P, and M fractions. 
In yeast, the cell wall retains most of the secreted proteins in 
the  periplasmic space.  These proteins can  be released in  a 
soluble form by converting cells to spheroplasts with a  lytic 
enzyme in  an  osmotically supportive medium.  Yeast cells 
were labeled with  355-H2504  for  15  min, followed by a  45- 
min chase period and fractionated into I and extracellular (E) 
fractions.  Fractions  corresponding to the  spheroplast pellet 
(I), spheroplast supernatant (P), and medium (M) were im- 
munoprecipitated with affinity-purified CPY antibody, and 
the resulting immunoprecipitates were solubilized and ana- 
lyzed by SDS polyacrylamide gel electrophoresis and fluorog- 
raphy. Cells not carrying a PRCI plasmid have only a little 
extracellular CPY (Fig.  2), indicating that sorting and trans- 
port to  the  vacuole normally is efficient.  In contrast,  cells 
transformed with pTSY3 (multicopy PRC1 plasmid) have a 
large fraction  of their CPY  in  the  E  fractions as  a  70-kD 
precursor CPY species (proCPY). The 70-kD species in the P 
fraction resembles the fully glycosylated intracellular proCPY 
(p2 CPY, 27) which is processed, probably in the vacuole, to 
produce the mature form of the enzyme (29). Cell lysis cannot 
account for the appearance of CPY in the E  fractions for if 
this were true the E and I fractions would exhibit the same 
forms of CPY.  Furthermore,  studies with antibody specific 
for the soluble cytoplasmic protein phosphoglycerate kinase 
indicate that cytoplasmic proteins were not detected in the E 
fractions (P, M) when CPY was overproduced and secreted 
(not shown). 
To define more precisely the role ofgene dosage in secretion 
of CPY,  the  PRC1  gene was subcloned  into  plasmids that 
provided  varying levels of CPY  overproduction.  A  3.6-kb 
EcoRI-Sal I  fragment that  contained PRC1  was subcloned 
into YCp50 (1) to obtain the single-copy plasmid pTSY1000 
(CEN-PRCI). A  high level overproduction plasmid was ob- 
tained  by  cloning  the  PRC1  gene  on  a  multiple-copy  2# 
plasmid. Quantitative comparison of PRC1  strains carrying 
plasmid YEp24  (no  plasmid-borne PRC1),  CEN-PRC1,  or 
2#-PRC1, showed that as overproduction of CPY increased, 
the percentage of CPY in the E fractions increased dramati- 
cally (Table  I  and  Fig.  2).  At  twofold  higher-than-normal 
levels of CPY synthesis (pTSY 1000), there is a small increase 
in extracellular CPY (12%) over the normal wild-type level 
(6%).  In contrast,  with  six- to  eightfold overproduction of 
CPY (2#-PRC1), ~50-55 % of the newly synthesized protein 
was directed to the cell surface. A comparable level of extra- 
cellular CPY was observed whether the nitrogen source in the 
growth medium was rich (ammonium chloride) or poor (pro- 
line).  Thus, between two- and sixfold enhanced synthesis of 
CPY appears to overload the CPY-sorting apparatus. Experi- 
ments in which the PRC1 gene was placed under the tran- 
scriptional control of the highly active PH05 or ADHI pro- 
moters did not result in levels of CPY synthesis significantly 
higher than were obtained with the PRC1 promoter. 
Figure 2.  Secretion of CPY in a  strain  carrying PRCl-containing 
plasmids. Exponentially growing cultures of ISY1-7Ba (PEP4) car- 
rying  various  plasmids  (2u:YEp24,  CEN-PRCI:pTSYIO00,  2u- 
PRCI:pTSY3) were labeled with 3SS-H2SO4 in the presence of 0.5 
mg/ml BSA for 15 min and 10 mM sulfate was added to initiate a 
45-min chase. Labeled cells were centrifuged, converted to sphero- 
plasts, and CPY immunoprecipitated from I, P, and M fractions. 
Table I. Overproduction of CPY Results in Secretion of the 
Protein 
Estimated PRCI  Relative CPY syn-  CPY 
Plasmid  gene copy number  thesis  secreted 
% 
2#  l  1  6 
CEN-PRCI  2  2  12 
2#-PRC1  >5  6-8  50-55 
Cultures  of  ISYI-7Ba  carrying  these  plasmids  (2#:YEp24,  CEN- 
PRCI:pTSYIO00, 2u-PRCI:pTSY3) were labeled with aSS-H2SO4 for 15 min, 
chased  in  medium-containing  excess Na2SO4 for 45  min,  centrifuged,  and 
fractionated  into I, P, and M fractions as before. Samples were analyzed for 
CPY by immunoprecipitation  and electrophoresis. Relative CPY synthesis was 
calculated  by quantifying  the intensity  of the CPY bands (22) expressed for 
each strain normalized for total 3SS-labeled protein. The pe~ent CPY secreted 
was determined  by quantitation  (I5) of the CPY  bands for the I, P, and M 
fractions from Fig. 2, where the percent secreted is 100 (P + M)/(I + P + M). 
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We have shown previously (29) that proCPY transits the early 
portion of the secretory pathway. CPY fails to be transported 
to the vacuole in endoplasmic reticulum-blocked and Golgi- 
blocked sec mutant cells incubated at the restrictive temper- 
ature (37"C); sec mutations that result in the accumulation of 
secretory vesicles  (vesicle-blocked  mutations)  do  not block 
transport  of proCPY to the  vacuole.  If overproduced CPY 
transits  the  remainder  of the  secretory  pathway  (Golgi 
secretory vesicles ~  periplasm), then a vesicle-blocked mutant 
(secl-1) should not secrete proCPY at 37"C. However, if the 
presence of extracellular CPY is due either to cell lysis or to 
mechanisms independent of secretion, then the secl mutation 
should not suppress the appearance of extracellular CPY. 
Yeast strain  SEY5016a (secl-1) carrying plasmid pTSY3 
was  labeled  with  35S-H:~SO4 at  25*  and  37"C.  Cells  were 
converted to spheroplasts and the three fractions examined as 
before. At 25"C, as expected, overproduced CPY was secreted 
(Fig. 3). At 37"C, however, secretion of proCPY was blocked 
and a portion of CPY (~50%) accumulated intracellularly as 
proCPY, whereas SEC1 ÷ cells carrying plasmid pTSY3 were 
found to secrete a high percentage of CPY (40-50%) at 37"C 
(not  shown).  Presumably  the  intracellular  proCPY seen  in 
secl cells at 37"C resides within secretory vesicles that accu- 
mulate  in  such  cells  (23).  Thus,  these  results  indicate  that 
extracellular CPY must reach the periplasmic space via the 
secretory pathway. 
Stability and Activation of  Secreted proCP Y 
Gene dosage-dependent appearance of external CPY could be 
accounted for by rapid degradation of  low levels of  the protein 
secreted  by cells with  only one or two copies of the PRC1 
gene. This possibility was examined in a  pulse-chase experi- 
ment designed to test the stability of secreted CPY. Cells were 
labeled  for  15  min  in  the  presence  of  1  mg/ml  BSA and 
chased  for  either  45  or  165  min  (Fig.  4).  Even  in  cells 
containing one copy of the PRC1 gene, a small percentage of 
proCPY (6%) escaped proper sorting, and was stable in both 
the  periplasm  and  medium  fractions over a  165-min chase 
period (Fig. 4). The stability of CPY in the medium fraction 
was greatly increased when BSA was present during the label- 
ing and chase period (not shown).  Very short chase periods 
did not reveal any additional forms of secreted CPY. Hence, 
the stability of the secreted proenzyme argues strongly against 
saturation ofextracellular CPY degradation as an explanation 
Figure 3. Secretory vesicle-accumulating mutant (secl-1) blocks se- 
cretion of  overproduced CPY. Yeast strain SEY5016a (secl-1, PEP4) 
carrying plasmid pTSY3 was labeled with ~55-H250, in the presence 
of BSA as described in Fig. 2 at 25* and 37*(?. Cells were collected, 
fractionated, and analyzed as before. 
Figure 4. Low level of CPY secreted by wild-type yeast cells is stable 
in the  extracellular  fractions.  Yeast  strain  ISY1-7Ba (PEP4) was 
labeled with BSA present as described in Fig. 2 except that one-half 
of  the culture was chased for 165 min. Cells were collected, fraction- 
ated, and analyzed for CPY as before, except that P and M samples 
were adjusted to have 20-fold more material loaded on the gel than 
the I samples to enhance detection of secreted CPY. 
Figure 5. Secreted p2 CPY is cleaved in the periplasm. Yeast strain 
SF838-1Da (pep4-3)  carrying plasmid pTSY3 (2~-PRC1)  was labeled 
and chased as described in Fig. 4 except that BSA was not added 
during the labeling or chase periods. Cells were collected, fractionated, 
and analyzed for CPY as before. 
for the gene-dosage response. 
Processing  of p2  CPY  to  mature  CPY  in  the  vacuole 
requires the PEP4 gene.  In the experiment shown in Fig. 4 
periplasmic material with a  mobility similar to mature CPY 
was detected after a 45-min chase and its relative abundance 
appeared to increase slightly during the 165-min chase. If this 
mature-size form is produced by a PEP4-dependent reaction, 
then periplasmic conversion should not occur in pep4 cells. 
To test this possibility, pep4 cells carrying the multiple-copy 
PRC1  plasmid were  35S-H2SO4 labeled  for  15  min without 
BSA and chased in the presence of excess NazSO4 for either 
45 or 165 min. After a 45-min chase, very little 61  kD CPY 
was observed in the I or E fractions (Fig. 5). In contrast, after 
a  165-min chase period, the P  fraction contained immuno- 
reactive protein with a mobility similar to mature CPY (Fig. 
5).  While  BSA  stabilized  proCPY  in  the  medium  during 
labeling and chase (-35%  CPY in the medium in Fig. 2  vs. 
<5% CPY in the medium in Fig. 5), it slowed the appearance 
of the mature-like CPY in the periplasmic space (not shown), 
possibly by inhibition of some cell-surface enzyme. Extracel- 
lular conversion of proCPY thus occurs by a reaction that is 
independent of the PEP4 gene, and can be inhibited by BSA 
in the labeling medium. 
The experiment  shown  in  Fig.  5  also  demonstrated  that 
secreted CPY (P and M  fractions) had the same etectropho- 
retic mobility as vacuolar p2 CPY, which accumulates in the 
The Journal of  Cell Biology,  Volume 102. 1986  1554 vacuole  (I  fraction)  of pep4 cells  as  a  result  of deficient 
proteolytic processing of the proenzyme (12, 29). To confirm 
that the polypeptide components of the secreted and vacuolar 
CPY precursors are similar, CPY from the I and E fractions 
of pep4 cells carrying plasmid pTSY3 was treated with Endo 
F  to  remove carbohydrate (4,  29)  and  electrophoresed on 
polyacrylamide gels.  Fig.  6  shows  that  the  deglycosylated 
extracellular and intracellular proCPY forms comigrate, in- 
dicating that the carbohydrate on secreted proCPY is indistin- 
guishable (by electrophoretic mobility) from that on vacuolar 
proCPY. This result shows that no additional detectable post- 
translational  modifications  accompany  proCPY  transport 
through the late stages of the secretory pathway. 
To determine if secreted periplasmic CPY was converted 
to  an  enzymatically active  form whole  cells  were  assayed 
using conditions in which substrate penetrated into the peri- 
plasm, but not into the cell. N-CBZ-L-phenylalanyl-L-leucine, 
a specific substrate for CPY (35),  was used to measure peri- 
plasmic activity.  For comparison, ceils were permeabilized 
with Triton X-100 to allow detection of all active CPY. Cells 
with  a  single  copy of PRC1  (Table  II,  strains without  the 
PRC1 plasmid) show background levels of periplasmic CPY 
activity. In contrast, PEP4 or pep4 cells carrying the multiple- 
copy PRC1 plasmid (2v-PRC1) show appreciable periplasmic 
CPY  activity (Table  II).  Confirming  the  results  in  Fig.  5, 
which show convened CPY only in the P  fraction, most of 
the enzymatically active CPY in the pTSY3-transformedpep4 
strain is periplasmic (Table II). 
Active secreted CPY was seen in transformed cells of both 
mating types and in bar1 cells carrying pTSY3 (not shown). 
Figure  6.  The  molecular  weights of deglycosylated secreted and 
vacuolar CPY presursors are similar. Yeast strain SF838-1Da (pep4- 
3) carrying plasmid pTSY3 (2tL-PRC1) was labeled with 35S-H2SO4 
in the presence of BSA as described in Fig. 2. Cells were collected, 
fractionated, and analyzed for CPY as before except that the P and 
M fractions were combined into the E fraction. The I and E fractions 
were treated with endo F as described, and subjected  to electrophoresis 
and autoradiography as before. Protein standards are given in kilo- 
daltons. 
Table H. Enzymatically Active CPY in the Periplasm 
CPY activity 
Intact  Permcabilized 
Strain  PEP4  Plasmid  cells  cells 
SF838 
-IDa  -  2it  1.2 -+ 0.2  1.7 + 0.4 
-IDa  -  2~-PRC1  8 +  I  10 +_ 1 
-SAa  +  2#  2.9 + 0.4  36 ± 5 
-5Aa  +  2#-PRC1  15 ± 3  95 ±  l0 
Cells carrying the indicated plasmids were grown to mid-log  phase, centrifuged, 
washed (+1% Triton X-IO0), and resuspended in either substrate or substrate 
plus 0.2% Triton X-100. CPY activity is given in milliunits per milligram dry 
weight. The 2u plasmid is YEp24 and the 2u-PRCI  plasmid is pTSY3. The 
results are the average  (and range) of five repeat assays. 
Thus, the BARI gene product, a  secreted protease that may 
proteolytically degrade  a-factor (3,  20),  appears not  to  be 
responsible for activation of the CPY precursor in the peri- 
plasm. 
Discussion 
We have shown that  a  high percentage of CPY is secreted 
when the dosage of its structural gene (PRC1) is increased. 
Although CPY is ordinarily localized almost exclusively to 
the  vacuole (-95%),  the  percentage  of proenzyme that  is 
secreted increases dramatically with elevated expression of the 
gene.  It is  possible that  at  some overproduction  level any 
additional  CPY synthesis results in  secretion  of the  excess 
newly-synthesized protein;  at  six- to  eightfold  higher-than- 
normal levels of CPY production,  >50%  of the  protein  is 
secreted. These results are consistent with titration of some 
component essential for transport of CPY to the vacuole. A 
similar situation may explain the recent report of a mamma- 
lian  cell  line  that  overproduces  and  secretes  a  lysosomal 
protein in maligantly transformed but not in normal cells (6). 
One interpretation of these data is that a limiting compo- 
nent, such as a  proCPY receptor in the Golgi body, is not 
sufficiently abundant to handle much more than a  twofold 
increase in  CPY levels.  When  the  receptor is saturated the 
unbound proenzyme is secreted. An equally plausible expla- 
nation  is that  some other component required  for sorting, 
such as an enzyme that modifies CPY in a way that is essential 
for sorting, is limiting, and unmodified CPY is secreted. Since 
glycosylation is not required for sorting of CPY, oligosaccha- 
ride modification is unlikely to be the limiting reaction for 
proper transport (26,  29). 
An alternative explanation for the gene dosage effect is that 
CPY overproduction results in the saturation of an extracel- 
lular protease that rapidly degrades high levels of  CPY secreted 
by cells with  new  copies of PRC1.  However, with  a  short 
labeling period designed to detect  newly synthesized mole- 
cules,  radiolabeled CPY is found in the E fractions even in 
normal cells, and this low level (6%) of secreted CPY is stable 
during a subsequent  165-min chase period. Hence even low 
levels of CPY are stable in the E fractions. These results argue 
strongly against limited extracellular turnover of CPY as an 
explanation for observing secretion at high PRC1 gene dosage. 
We have also considered the possibility that overproduction 
leads to aggregation of proCPY within the lumenal space of 
the endoplasmic reticulum or GolD. Aggregated protein may 
not expose the targeting signals to the sorting component(s). 
However, secreted proCPY is accessible to the Golgi mannosyl 
transferases that act to convert pl to p2 CPY during normal 
transport to the vacuole. In addition, a second yeast vacuolar 
enzyme, proteinase A, also exhibits overproduction-induced 
secretion  (24),  and  thus  proteinase  A  would  also  have to 
aggregate to the same extent at the same level of overproduc- 
tion as CPY. Nevertheless, though we consider saturation of 
a limited quantity of transport sites a more likely explanation 
of the data, a sorting-deficient aggregate cannot be ruled out. 
Detection  of a  saturable  binding  component  by  in  vitro 
reconstitution will allow these possibilities to be distinguished. 
If a single receptor is involved in the transport of a family 
of vacuolar  proteins,  saturation  by overproduction  of one 
member should result in  secretion of the related members. 
This remains a possibility, although in strains carrying PRC1 
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enzymatically active alkaline phosphatase, or immunoreac- 
tive proteinase A  polypeptide, two other vacuolar proteins 
(Rothman, J.  H., and T.  H. Stevens,  unpublished observa- 
tions). A more general approach may be needed to monitor 
secretion of a wider range of vacuolar proteins. 
In  the  normal  transit  of CPY  to  the  vacuole a  67-kD 
glycoprotein precursor form (produced in  the endoplasmic 
reticulum) is glycosylated further in the Golgi body to yield a 
70-kD species (p2 CPY). When CPY is secreted, the same 70- 
kD form is detected in the periplasm (with the same comple- 
ment  of carbohydrate) where  it  is  slowly converted to  an 
enzymatically active  form.  Invertase,  a  normally  secreted 
enzyme, undergoes considerably more extensive glycosylation 
in the Golgi body where a  79-83-kD form is converted to 
heterogeneous  forms of  100-150  kD  (5).  While  the  secl 
experiment suggests that CPY likely transits the entire secre- 
tory pathway, the extent of glycosyl modification appears to 
be an inherent property of CPY itself and not simply a result 
of spatial separation from the glycosyl transferases that act on 
secreted enzymes. However, this conclusion assumes that the 
secl block defines a unique secretory pathway and not mul- 
tiple parallel pathways, a point yet to be resolved. 
This situation differs from that observed in the mislocali- 
zation oflysosomal enzymes in fibroblasts from I-cell disease 
(mucolipidosis  II) patients.  Unlike  secretory glycoproteins, 
lysosomal enzyme oligosaccharides are phosphorylated in the 
Golgi body. This modification allows targeting to the lyso- 
some by interaction  with a  mannose-6-phosphate receptor, 
and prevents conversion of lysosomal oligosaccharide chains 
from the high-mannose to complex form (28).  I-cell fibro- 
blasts lack the enzyme that phosphorylates lysosomal enzyme 
oligosaccharides (11).  In the  absence  of this  modification, 
lysosomal enzymes undergo  the  normal  high  mannose  to 
complex oligosaccharide conversion and are secreted (9, 28). 
Conversion of the secreted proCPY to active CPY is me- 
diated by an unknown activity; this process occurs independ- 
ently of the PEP4 gene product which is required for activa- 
tion of many hydrolytic enzymes within  the vacuole. Since 
trypsin can convert proCPY to a mature-like CPY species (8) 
that is enzymatically active (36), periplasmic maturation may 
be  mediated  by  a  secretory  or  plasma  membrane surface 
endoprotease  of similar  specificity.  The  activation  of the 
secreted precursor allows a genetic selection for mutants that 
mislocalize CPY.  Mutations  in  the  sorting apparatus (e.g., 
CPY receptor) may be obtained by selecting for cells capable 
of growth on a peptide which must be cleaved by periplasmic 
CPY to provide a necessary nutritional supplement (30). This 
approach should aid in the identification of molecules that 
participate in the sorting reaction. 
In conclusion,  by modulating the level of CPY synthesis 
through PRCI gene dosage experiments, we have demonstra- 
ted that proper transport of this glycoprotein to the vacuole 
can be overloaded. Our results suggest that CPY transport to 
the vacuole may be mediated by a saturable component such 
as a  receptor. Unlike the mannose-6-phosphate receptor of 
mammalian cells,  the yeast receptor would most likely rec- 
ognize protein determinants since transport of CPY does not 
require glycosylation. Although excess CPY transits the entire 
secretory pathway, it does not undergo the glycosyl modifi- 
cations characteristic of typical secreted yeast glycoproteins. 
This result indicates that glycosyl modifications in yeast may 
be dictated by structural  properties inherent  in the protein 
undergoing the modifications, and not merely by exposure to 
the transferases. 
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